StemCells, Inc. (NASDAQ:STEM) on 20 June Friday announced that, it has closed enrollment in its Phase I/II clinical trial for dry age-related macular degeneration or AMD for focussing its attention on a follow-on Phase II randomized, controlled proof-of-concept study, later this year. Interim results for the AMD trial showed a 70 percent reduction in the rate of geographic atrophyor or GA compared with the control eye and a 65 percent reduction in the rate of GA compared with the expected natural histo StemCells Inc. (NASDAQ:STEM) weekly performance is 40.79%. On last trading day company shares ended up $2.14. Analysts mean target price for the company is $4.00. StemCells Inc. (NASDAQ:STEM) distance from 50-day simple moving average (SMA50) is 58.40%.
US health care giant Johnson & Johnson (NYSE:JNJ), through its J&J Innovation unit, announced 12 new alliances with life science companies and research institutions around the globe to explore early-stage innovation in a broad range of therapeutic areas and across pharmaceuticals, medical device and diagnostics and consumer health care. Johnson & Johnson (NYSE:JNJ) shares advanced 1.41% in last trading session and ended the day on $105.27. JNJ gross Margin is 69.10% and its return on assets is 11.60%.Johnson & Johnson (NYSE:JNJ) quarterly performance is 10.50%.
St. Jude Medical Inc. (NYSE:STJ) on 20 June revealed that it has received the 2014 Innovation Award at Cardiostim 2014, the 19th World Congress in Cardiac Electrophysiology and Cardiac Techniques for its Nanostim leadless pacemaker. St. Jude Medical, Inc. (NYSE:STJ) shares moved up 3.08% in last trading session and was closed at $69.84, while trading in range of $68.09 – $69.86. St. Jude Medical, Inc. (NYSE:STJ) year to date (YTD) performance is 13.21%.
Lannett Company Inc. (NYSE:LCI) major shareholder David Farber sold 10,000 shares of the company’s stock on the open market in a transaction dated Monday, June 16th. The stock was sold at an average price of $43.53, for a total value of $435,300.00. Following the sale, the insider now directly owns 77,500 shares in the company, valued at approximately $3,373,575. Lannett Company, Inc. (NYSE:LCI) ended the last trading day at $49.76. Company weekly volatility is calculated as 3.36% and price to cash ratio as 14.33.Lannett Company, Inc. (NYSE:LCI) showed a positive weekly performance of 6.60%.
On June 11, 2014, OraSure Technologies Inc. (NASDAQ:OSUR) announced that it has entered into a Master Program Services and Co-Promotion Agreement with AbbVie Inc. under which the companies will co-promote the OraSure’s OraQuick® HCV Rapid Test (for testing individuals at-risk for hepatitis C) in the U.S. According to the Company, it has granted exclusive promotion rights to AbbVie for the OraQuick® HCV test in certain markets, along with providing certain additional services in support of HCV testing. OraSure Technologies, Inc. (NASDAQ:OSUR) net profit margin is -6.50% and weekly performance is 10.63%. On last trading day company shares ended up $8.95. Analysts mean target price for the company is $9.25. OraSure Technologies, Inc. (NASDAQ:OSUR) distance from 50-day simple moving average (SMA50) is 32.95%.